Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Super Lysine+ is a multi-ingredient nutraceutical formulation primarily indicated for the treatment and prophylaxis of Herpes simplex virus (HSV-1) infections, specifically herpes labialis (cold sores). The therapeutic mechanism is centered on the amino acid L-lysine, which acts as a competitive antagonist against L-arginine. Because HSV requires arginine-rich proteins for efficient replication, a high systemic or local lysine-to-arginine ratio suppresses viral protein synthesis and inhibits viral multiplication. The product line, which includes both oral tablets and topical ointments, typically incorporates synergistic components such as Vitamin C to support collagen formation and tissue repair, along with botanical extracts like Echinacea, Garlic, and Propolis to enhance the host's innate immune response and provide broad-spectrum antimicrobial activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Super Lysine+.